Citations

Clear

126 citation(s) found for "McDonnell, A".

nanoASM: Long-Read Allele-Specific DNA Methylation Profiling Enables Functional Annotation of Regulatory Noncoding Variants in Human Prostate Tissues
Tian, Yijun , Wong, Jodie , Zhong, Hua , Wu, Lang, Larson, Nicholas B. , Manley, Brandon J. , Wang, Liang, McDonnell, Shannon K , Larson, Nicholas B , Manley, Brandon J , McDonnell, Shannon K. , Wu, Lang, Wang, Liang

Mayo Clinic

No container title available | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.732357 | PMID 42395488 Get It

Summary Long-read nanopore sequencing enables simultaneous detection of germline variation and native DNA base modifications on individual DNA molecules, providing a unique opportunity to investigate allele-specific epigenetic regulation. Here, we performed whole-genome nanopore sequencing on normal and tumor prostate tissues to characterize differential methylation, methylation entropy, and allele-specific methylation (ASM) associated with noncoding genetic variants. Genome-wide analysis identified extensive cancer-associated differentially methylated regions (DMRs), with hypermethylated DMRs significantly enriched near transcription start sites and transcriptional regulatory regions. Integration with transcriptomic datasets revealed strong inverse relationships between promoter methylation and gene expression, while 5-hydroxymethylcytosine (5hmC) levels positively correlated with transcriptional activity across gene bodies. Using fragment-level methylation patterns enabled by long-read sequencing, we further quantified methylation entropy incorporating both 5mCG and 5hmCG states. Cancer-hypermethylated DMRs exhibited markedly reduced entropy, consistent with clonal fixation of methylation states during tumor progression. Entropy profiling across chromatin annotations demonstrated maximal epigenetic heterogeneity at partially modified enhancer-associated regions. To investigate cis-regulatory genetic effects, we developed a simple ASM framework (nanoASM) that can partition sequencing reads by allelic state and identifies allele-specific DMRs directly from long-read data. Compared with conventional population-level mQTL analysis, ASM demonstrated substantially improved statistical efficiency by leveraging within-individual contrasts and reducing sample-level heterogeneity. Although germline single nucleotide polymorphisms (SNPs) were largely shared between normal and tumor tissues, ASM patterns differed substantially, with tumor-associated ASM regions displaying significantly larger genomic span and stronger allelic methylation differences. Comparative analysis with TCGA prostate mQTL and GTEx prostate eQTL datasets demonstrated substantial concordance between ASM directionality and downstream transcriptional effects, particularly for variants located within DMRs and near transcription start sites. At the IRX4 prostate cancer risk locus, ASM identified an androgen-responsive regulatory domain overlapping AR ChIP-seq and H3K27ac peaks, nominating rs6885084 as a candidate functional variant. At the PSCA locus, ASM anchored by rs4736369 was associated with allele-specific methylation, chromatin activation, transcript abundance, and isoform usage. Together, these findings establish nanopore-based ASM analysis as a powerful approach for resolving functional noncoding variants and their regulatory domains they control in prostate cancer.
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
Braun, David, Dana, Nicholas, Hernan, Hilary R., Scribano, Christina, Johnson, Christin , Vedder, Lindsey, Euw, Erika von , Zweng, Julie, Wargowski, Ellen, Sunil, Aishwarya , Sharma, D, Routh, Josh, Rexroad, Katherine, McDonnell, Payton , Jergens, Victor, Costa, Catarina, Zuniga, Richard, Patel, Paras M., Martin, Robert C.G., Majeed, Umair, Mukhopadhyay, Debabrata, Lou, Yanyan, Kokabi, Nima, Jakub, James W., Hays, David, Godwin, Andrew K., Giffi, Victoria, Gelbard, Alexander, Friedl, Andreas, Duimstra, Emma Kate, Dronca, Roxana S., Chen, Ruqin, Chalfin, Heather, Broome, Barbara , Babiker, Hani M., Chandra, Tarun, Caenepeel, Sean, Hrycyniak, Laura , Sood, Chetan , Ramos, Hilario, Patel, Premal , Advani, Pooja, Gierman, Hinco J., Taube, Janis, Braun, David , Sahni, Shalini, Scribano, Christina M. , Wargowski, Ellen , Zuniga, Richard, Toia, Giuseppe V. , Martin, Robert C.G. , Majeed, Umair , Mukhopadhyay, Debabrata , Lou, Yanyan , Kokabi, Nima , Jakub, James W. , Godwin, Andrew K. , Gelbard, Alexander , Friedl, Andreas , Dronca, Roxana , Chen, Ruqin, Chalfin, Heather J., Babiker, Hani M. , Caenepeel, Sean , Ramos, Hilario J. , Patel, Premal, Advani, Pooja , Gierman, Hinco J. , Taube, Janis M

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.26354635 Get It

Summary Functional ex vivo assays using live tumor tissues have demonstrated strong predictive accuracy for response to immune checkpoint inhibitors (ICIs) but are not scalable, requiring manual processing of large resections collected at academic centers. Here, an ex vivo live tumor fragment (LTF) platform was developed using standard-of-care biopsies from 228 patients with suspected malignancy collected across prospective, multicenter observational trials and biobanks. Hierarchical clustering of ICI-mediated changes in cytokine production identified two groups: responders and nonresponders. A binary classifier (elive index) using 8 cytokines achieved an AUC of 0.99 for cluster prediction. elive index correctly predicted clinical benefit in 93% (26/28) of patients ( P = 3.2x10 -5 ) and accurately identified 83% (10/12) of objective responders. Critically, elive responders were identified among biomarker-negative patients, highlighting the platform as a scalable approach that complements existing companion diagnostics and expands the population of patients identified to benefit from ICI therapy.
Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.
Giridhar, Karthik, McDonnell, Charles H. , Kurbegov, Dax, Matrana, Marc , Gadgeel, Shirish M., Kim, Raymond, Stipec, Gretchen, Oeffinger, Kevin C., Demeure, Michael J. , Lillard, James W., Kaltman, Rebecca , Tran, Jennifer, Roth, Alan , TAHHAN, SAMI, Richards, Donald A., Lopatin, Rita, Marquez, Celine, Nabavizadeh, Nima , Gadgeel, Shirish M. , Oeffinger, Kevin C. , Lillard, James W., Tahhan, Sami, Poklepovic, Andrew , Richards, D., McCusker, Margaret

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba10509 Get It

LBA10509 Background: The MCED test (Galleri) detects a shared cancer signal from cell-free DNA in blood and predicts a cancer signal origin (CSO) to guide diagnostic (dx) workup. PF2 (NCT05155605) is a large, prospective, multicenter, interventional study of the MCED test’s performance and safety in a diverse US intended-use population. Methods: PF2 enrolled participants aged ≥50y without clinical suspicion of cancer or cancer diagnosis/treatment within 3y of enrollment. Primary objectives were MCED performance and safety in terms of dx testing triggered by a positive (cancer signal detected) MCED test result. Participants with a positive MCED test underwent targeted dx workup guided by the predicted CSO(s). Participant-reported anxiety was assessed with the State Trait Anxiety Inventory. Results: PF2 enrolled 35,878 participants; 32,007 with a 12m cancer assessment were analyzable for performance. Of 287 (0.9%) with a positive MCED test, 173 were diagnosed with cancer within 12m, for a cancer detection rate of 0.5% (95% CI 0.5-0.6%) and positive predictive value of 60.3% (54.5-65.8%). Specificity was 99.6% (99.6-99.7%). 12m episode sensitivity was 69.8% (62.8-76.0%) in a prespecified subgroup of 12 cancers responsible for ⅔ of US cancer deaths, 66.2% (55.1-75.8%) in a subgroup of 6 aggressive cancers with low 5y survival, and 39.3% (34.9-44.0%) across all cancers. Overall CSO prediction accuracy was 91.3% (86.2-94.7%) across all cancers. The MCED test detected 151 new primary and 22 recurrent cancers; additional cancers detected by screening were those with USPSTF A/B (n=31) and C (n=60) recommended screening. Of 151 MCED-detected new primaries, 80 (53.0%) were clinical stage I-II; 107 (70.9%) were stage I-III. Of 80 MCED-detected stage I-II cancers, 71.2% had no USPSTF A/B screening recommendation. Of 35,335 participants analyzable for safety, 213 (0.6%) had invasive procedure(s) to evaluate a positive MCED test result, of which 90% were nonsurgical and 1.8x more likely for participants with vs without cancer diagnosis. Most (87.6%) had a CSO-guided dx evaluation. There were 5 study-related adverse events during the time of dx workup; none were serious. Anxiety temporarily increased for participants with a positive MCED test and cancer diagnosed, and returned to baseline by 12m. Of participants with a positive MCED test, median time from test result to dx resolution was 48d (95% CI 43-56). Few participants (7/63 [11.1%]) had cancer found by dx PET/CT after a targeted dx workup that did not reveal cancer. Conclusion: The MCED test demonstrated robust performance with a favorable safety profile. When MCED testing was added to USPSTF A/B screening, 6.5x more cancers were detected by screening, most at early stages. The diverse, representative PF2 participant population supports the generalizability of these findings to the US intended-use population. Clinical trial information: NCT05155605 .
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026
Cheng, Heather H., Goggins, Michael, Yurgelun, Matthew B. , Karlan, Beth Y., Norquist, Barbara S., Daly, MB, Pal, Tuya, AlHilli, Zahraa, Arun, Banu , Churpek, Jane, Colonna, Sarah, Domchek, Susan M., Escobar, Mauricio R., Friedman, S, Hagemann, Andrea, Hendrix, Ashley, Huo, Dezheng, Hutton, Mollie L., Kassem, Nawal , Kurian, Allison W., Laronga, Christine , Mak, Julie S, McDonnell, Kevin, Mersch, Jacqueline, Offit, Kenneth, Plichta, Jennifer K. , Rash, Dominique , Reiser, Gwen , Senter-Jamieson, Leigha, Shannon, K. McWeeney, Welborn, Jeanna, Wick, Myra , Wood, Marie , Darlow, Susan, Diwan, Zeenat, Dwyer, Mary, Churpek, Jane E. , Kurian, Allison W. , Kurian, Allison W , Plichta, Jennifer K , Churpek, Jane E , Churpek, Jane , Giri, Veda N. , Goggins, Michael, Karlan, Beth Y , Norquist, Barbara, Pal, Tuya , Al‐Hilli, Zahraa , Arun, Banu , Colonna, Sarah V. , Domchek, Susan M. , Fejerman, Laura , Hagemann, Andrea, Huo, Dezheng , Khan, Seema A. , Mak, Julie , Maxwell, Kara N. , McDonnell, Kevin , Merajver, Sofía D. , Mersch, Jacqueline A, Offit, Kenneth , Darlow, Susan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 2-10

10.6004/jnccn.2026.0007 | PMID 41671423 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.
Abstract C145: Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting
Nabavizadeh, Nima , Kurbegov, Dax, McDonnell, Charles H. , Lillard, James W., Matrana, Marc , Roth, Alan, Johnston, Andrea, Tahhan, Sami, Owera, Rami, Kansal, Anuraag, Lopatin, Margarita , Gadgeel, Shirish M. , Margolis, Matthew L. , Kansal, Anuraag, McCusker, Margaret , Giridhar, Karthik V.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 18, 2025 | Volume: 34 | Issue: 9_Supplement | Pages: C145-C145

10.1158/1538-7755.disp25-c145 Get It

Abstract A blood-based multi-cancer early detection (MCED) test has demonstrated feasibility as a screening tool in large-scale clinical trials. The PATHFINDER 2 (PF2) study (NCT05155605) evaluates safety and performance of the MCED test in a diverse intended-use population. To gauge generalizability of study results, we assessed participant (ppt) baseline characteristics vs general US population data from the National Health and Nutrition Examination Survey (NHANES). PF2, a prospective, multicenter, interventional study, enrolled ppts aged ≥50 y from diverse clinical settings in North America. Enrollment targets for sex and race/ethnicity were established from the 2019 American Community Survey (US Census Bureau). Recruitment strategies were implemented to maximize enrollment for groups historically underrepresented in clinical studies. Exclusion criteria included clinical suspicion of cancer or cancer diagnosis/treatment within 3 y. Data on baseline characteristics and key cancer risk factors were collected at enrollment. We compared the PF2 study population to a nationally representative sample of US adults aged ≥50 y from 2017-2020 NHANES data. NHANES data were weighted using complex, multistage probability sampling to generate a nationally representative sample. There were 35,878 ppts enrolled in PF2; 35,307 clinically eligible and evaluable ppts were included in this analysis. Mean age was 64 y for both PF2 and NHANES; 56.2% were females in PF2 vs 53.6% (95% CI 52.0-55.3%) in NHANES. Race/ethnicity distribution for PF2 vs NHANES was 7.4 vs 11.0% (8.9-13.1%) Hispanic, 74.6 vs 69.7% (65.0-74.5%) non-Hispanic (NH) White, 8.6 vs 10.3% (7.6-13.1%) NH Black, and 5.8 vs 5.1% (3.5-6.8%) NH Asian. In terms of lifestyle characteristics for PF2 vs NHANES, 58.9 vs 29.2% (25.8-32.7%) had at least a bachelor’s degree, 74.8 vs 63.8% (60.6-67.0%) were married/living with a partner, 69.3 vs 53.8% (50.9-56.7%) had never smoked, 66.5 vs 70.4% (68.0-72.8%) were overweight/obese, and 24.2 vs 28.4% (26.4-30.3%) reported never using alcohol. PF2 enrolled a diverse ppt population that is reasonably reflective of the demographics of the US population aged ≥50 y. As is typical for clinical trials, a higher percentage of PF2 vs NHANES ppts reported lifestyle characteristics associated with better health. As the study population largely reflects the MCED test intended-use population, safety and performance results from PF2 are expected to reflect real-world clinical experience. Citation Format: Shirish Gadgeel, Nima Nabavizadeh, Dax Kurbegov, Charles McDonnell, III, James W. Lillard, Jr., Marc Matrana, Alan Roth, Andrea Johnston, Sami Tahhan, Rami Owera, Matthew Margolis, Anuraag Kansal, Margarita Lopatin, Margaret McCusker, Karthik V. Giridhar. Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting [abstract]. In: Proceedings of the 18th AACR Conference on the Science of Cancer Health Disparities; 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr C145.
A Multiomics Study of Circulating Proteins and Kidney Stone Risk
Zhou, Le‐Ting , Stark, Isaac W. , Jayachandran, Muthuvel , Harris, Peter C. , Rule, Andrew D. , Koo, Kevin , Larson, Nicholas B. , Lieske, John C. , Larson, Nicholas B , Lieske, John C , Rule, Andrew D , Harris, Peter C , McDonnell, Shannon K.

Mayo Clinic

Journal of the American Society of Nephrology | June 27, 2025 | Volume: 36 | Issue: 12 | Pages: 2456-2468

10.1681/asn.0000000768 | PMID 40577066 Get It

Key Points Circulating proteins independently associated with kidney stone diagnosis are related to kidney stone matrix. Lower circulating uromodulin and higher scavenger receptor cysteine-rich domain-containing group B protein levels were associated with higher kidney stone risk, whereas kidney stone presence elevates plasma matrix metalloproteinase 7 level. The protective effect of uromodulin against kidney stones was independent of kidney function. Background Kidney stones are increasingly recognized as a systemic disorder with a high global prevalence. However, large proteomics studies are lacking. Methods An individual-level proteomics study with rigorous adjustments was performed on 35,331 UK Biobank participants to uncover the independent associations between 2922 circulating proteins and prevalent kidney stone disease. Mendelian randomization analysis was used to assess causal relationships. Findings were validated using genomic data from the Mayo Clinic Biobank ( N =43,744), concentration-response analysis, transcriptomics analyses, and additional genome-wide association studies. Results Nine plasma proteins were independently associated with a kidney stone diagnosis, including reduced uromodulin (UMOD; β , −0.10; 95% confidence interval [CI], −0.15 to −0.05) and elevated scavenger receptor cysteine-rich domain-containing group B protein (SSC4D; β , 0.28; 95% CI, 0.17 to 0.38) and were enriched in extracellular matrix pathways. Mendelian randomization analysis revealed that the presence of kidney stone contributed to elevated levels of matrix metalloproteinase 7. Conversely, lower plasma UMOD (odds ratio [OR], 0.93; 95% CI, 0.90 to 0.97) and higher plasma SSC4D (OR, 1.10; 95% CI, 1.02 to 1.18) were associated with kidney stone risk. These associations were consistently replicated in the Mayo Clinic Biobank dataset (UMOD; OR, 0.92; 95% CI, 0.86 to 0.98; SSC4D; OR, 1.13; 95% CI, 1.01 to 1.27) and further validated by a concentration-response analysis. Single-nucleus RNA sequencing and quantitative trait loci analyses confirmed consistent associations between thick ascending limb UMOD expression and stone former status and with blood and urine UMOD concentrations. Genome-wide association study analysis, adjusted for eGFR, suggested that the protective role of UMOD against kidney stones was independent of kidney function. Conclusions This study highlights significant associations between concentrations of specific blood proteins and a history of kidney stones. Several implicated proteins are related to kidney stone matrix, with UMOD independently associated with lower risk and SSC4D with higher risk of kidney stones.
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Janas, Anastasia , Baid, Ujjwal , Ramakrishnan, Divya , Saluja, Rachit , Ashraf, Nader, Maleki, Nazanin , Yordanov, Nikolay , Fehringer, Pascal, Gkampenis, Athanasios , Amiruddin, Raisa, Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammad, Bergquist, Timothy , Chiang, Veronica , Eddy, J. Mark , Ezhov, Ivan , Khalili, Nastaran, Jiang, Zhifan , Johanson, Elaine, Kazerooni, Anahita Fathi , Krantchev, Kiril, Linguraru, Marius George , Liu, Xinyang , Meier, Zeke, Moy, Harrison, Osenberg, Klara , Reitman, Zachary, Shinohara, Russell Takeshi, Wang, Chunhao , Shafique, Umber, Willms, Klara, Avesta, Arman , Bousabarah, Khaled , Chakrabarty, Satrajit , Gennaro, Nicolò , Holler, Wolfgang, Lost, Jan , Marcus, Daniel S. , Maresca, R, Merkaj, Sarah, Pedersen, Gabriel Cassinelli, Reppert, Marc von , Teytelboym, Oleg M., Tillmans, Niklas, Westerhoff, Malte , Youssef, Ayda , Pflüger, Irada, Perez-Carillo, Gloria J. Guzman, Memon, Fatima, Krycia, Mark, Patro, Satya Narayana , Petrović, Bojan , Schrickel, E. Brooke, Besada, Cristina , Chu, Sammy, Dusoi, Alexandru, Farage, Luciano , Fong, Amy, Gray, R. Ian, Krumpelman, Chase, Lincoln, Christie M. , Maros, Máté E. , Morón, Fanny , Nimchinsky, Esther A. , Patel, Uresh, Rohatgi, Saurabh , Sayah, Anousheh , Schwartz, Eric D. , Shiroishi, Mark S. , Valerie, Jewels, White, Matthew L. , Zohrabian, Vahe M. , Brüßeler, Melanie, Ghonim, Mohamed, Okar, Abdullah , Pasquini, L. , Soumala, Theodora, Taherzadeh, Mahsa , Vollmuth, Philipp, Foltyn, Martha , Abayazeed, Aly, Dellepiane, Francesco , Verdier, Maria Correia de , Al-Rubaiey, Sanaria, Ashraf, Kholod, Asla, Moamen M., Badawy, Mohamed , Lomer, Nima Broomand , Bukatz, Jan, Chen, Jim, Cimflová, Petra , Corr, Felix, Crawley, Alexis, Deptula, Lisa, Elakhdar, Tasneem, Shawali, Islam H., Frick, Alexandra, Haider, Muhammad Ammar , Hierro, Fátima , Jacobs, Sarah Maria, Hsieh, Kuang-chun Jim, Kersting, Katharina , Kida, Laura, Kollia, Sofia , Koukoulithras, Ioannis, Li, Xiao , Abouelatta, Ahmed, Mansour, Aya, Maria-Zamfirescu, Ruxandra-Catrinel, Marsiglia, Marcela , Mateo-Camacho, Yohana Sarahi , McArthur, Mark J., McDonnell, Olivia, McHugh, M, Moassefi, Mana , Morsi, Samah Mostafa, Munteanu, Alexander , Naqvi, Syed Raza, Nikanpour, Yalda , Alnoury, Mostafa , Nouh, Abdullah Mohamed Aly, Pappafava, Francesca, Patel, Markand D., Petrucci, S. , Rawie, Eric, Raymond, Scott B. , Roohani, Borna, Sabouhi, Sadeq, Sánchez‐García, Laura , Shaked, Zoe , Altes, Talissa A. , Isufi, Edvin , Dhemesh, Yaseen , Gass, Jaime, Thacker, Jonathan, Tarabishy, Abdul , Turner, Benjamin , Worede, Fikadu , Yousry, Sara, Lerebo, Wondwossen , Aristizábal, Alejandro , Karargyris, Alexandros , Kassem, Hasan , Sheller, Micah , Link, Katherine E. , Moawad, Ahmed W. , Ashraf, Nader, Jekel, Leon , Manteghinejad, Amirreza , Aneja, Sanjay , Anwar, Syed Muhammad, Chung, Verena , Conte, Gian Marco , Dako, Farouk , Eddy, James, Khalili, Nastaran, Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Piraud, Marie , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Kaur, Manpreet , LaMontagne, Pamela , Lin, MingDe , Maresca, Ryan, Petersen, Gabriel Cassinelli , Sotiras, Aristeidis , Godfrey, Devon , Floyd, Scott , Rauschecker, Andreas M. , Villanueva-Meyer, Javier E. , Cho, Jaeyoung , Bendszus, Martin , Brugnara, Gianluca , Cramer, Justin , Johnson, Derek R. , Kam, Anthony , Kwan, Benjamin Y. M. , Lai, Lillian M. , Lall, Neil , So, Tiffany Y. , Thompson, Gerard , Wu, Lei , Bansal, Anu , Barkhof, Frederik , Druzgal, T. Jason , Feltrin, Fabrício Stewan , Fung, Steve H. , Ikuta, Ichiro , Iv, Michael , Postma, Alida A. , Mahajan, Amit Kumar , Joyner, David , Létourneau‐Guillon, Laurent , Miller, Elka , Özsarlak, Ö. , Saha, Atin , Shih, Robert , Small, Juan E. , Tanwar, Manoj , Weinberg, Brent D. , Young, Robert J. , Azizova, Aynur , Ghonim, Mohanad , Ghonim, Mohamed, Sharifi, Yasaman , Singh, Gagandeep, Sollmann, Nico , Vollmuth, Philipp, Foltyn‐Dumitru, Martha , Malhotra, Ajay , Lohmann, Philipp , Pérez‐García, Víctor M. , Elhalawani, Hesham M. , Duarte Armindo, Rui , Asla, Moamen M., Bisschop, Jeroen , Faghani, Shahriar , Gulati, Vaibhav , Dahl, Rasmus Holmboe , McArthur, Mark, McHugh, Maire, Moassefi, Mana , Nandolia, Khanak , Petrucci, Samantha, Sanchez-Garcia, Laura M., Suthar, Pokhraj Prakashchandra , Vacca, Sebastiano , Vilanilam, George K. , Warren, Daniel, Weiss, David, Pati, Sarthak , Calabrese, Evan , Tahon, Nourel Hoda , Nada, Ayman , Velichko, Yury , Bakas, Spyridon , Rudie, Jeffrey D. , Aboian, Mariam

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: December 2025 | Pages: 204-247

10.59275/j.melba.2025-9bd3 Get It

The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. The mean scores for the teams were calculated. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. The Dice score for the winning team was 0.65 ± 0.25. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space. The Dice scores and lesion detection rates of all algorithms diminished with decreasing tumor size, particularly for tumors smaller than 100 mm3. In conclusion, algorithms for BM segmentation require further refinement to balance high sensitivity in lesion detection with the minimization of false positives and negatives. The BraTS-METS 2023 challenge successfully curated well- annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied environments and providing the tools for future development of personalized volumetric reports to patients undergoing BM treatment.
Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
Marinac, Catherine R. , McDonnell, Charles H. , Nadauld, Lincoln , Dilaveri, Christina A. , Reid, Robert , Chung, Karen , Lopatin, Margarita , Fung, Eric T. , Schrag, Deborah , Shaknovich, Rita , Klein, Eric A. , Klein, Eric A. , Nadauld, Lincoln D , Chung, Karen C , Klein, Eric A , Marinac, Catherine R , Schrag, Deborah

Mayo Clinic

Cancer Prevention Research | April 23, 2025 | Volume: 18 | Issue: 8 | Pages: 475-483

10.1158/1940-6207.capr-24-0468 | PMID 40265568 Get It

Abstract Blood-based multicancer early detection (MCED) tests represent a new approach for cancer detection. To gain insights into the utility of various approaches of evaluating a cancer signal detected (CSD) test result, we evaluated diagnostic journeys of a subset of 6,662 participants in PATHFINDER who had a CSD on both an initial and refined version of an MCED test that also provided a prediction of cancer signal origin (CSO). We sought to determine whether CSO prediction–guided diagnostic evaluations led to diagnostic resolution; whether participants with known risk factors for cancer beyond age alone and a negative initial diagnostic evaluation had a cancer diagnosis during study follow-up; the utility of whole-body imaging in reaching diagnostic resolution; and differences in the diagnostic journeys needed to reach diagnostic resolution for both true- and false-positive results. Of the 39 participants in this analysis, 82% (32/39) achieved diagnostic resolution after the initial evaluation, including 78% (25/32) who reached resolution specifically with a CSO prediction–directed workup. Eighteen percent (7/39) required additional evaluation for persistent clinical suspicion of cancer, all of whom achieved resolution (3 with and 4 without cancer). Whole-body imaging contributed to diagnostic resolution in only 49% of CSD cases. Approximately 90% of true- and false-positive cases had imaging tests; more true positives versus false positives (81.0% vs. 38.9%) had nonsurgical and/or surgical procedures. In conclusion, CSO prediction–directed evaluations enabled diagnostic resolution for most participants, although some with negative initial evaluations but persistent suspicion of cancer required additional testing. Prevention Relevance: MCED testing has the potential to increase detection of cancer at earlier stages. As MCED testing is a new technology, there are few data on the diagnostic journeys patients undergo following testing. We observed that for most patients, CSO prediction–directed workups were efficient, leading to diagnostic resolution after initial evaluation.